Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Combined Epoprostenol Sodium & Milrinone

Phase 2Small molecule

MMontreal Heart Institute

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Right Heart FailureRecruiting

Right Heart FailurePhase 2

Recruiting

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Right Heart Failure

NCT05450328

Clinical

Trials by Indication[1]

Right Heart Failure1 trial

Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial

Recruiting·MMontreal Heart Institute·Phase 2·NCT05450328·141 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Combined Epoprostenol Sodium & Milrinone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combined Epoprostenol Sodium & Milrinone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combined Epoprostenol Sodium & Milrinone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Montreal Heart Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMontreal Heart Institute

Related News